Global Bronchodilators Market- By Drug-Class, Applications, and Route of Administration, Regions and Forecast 2019-2027

The Global Bronchodilators Market was valued at $XX Mn in 2019 and is expected to reach $XX Mn in 2027, registering a CAGR of XX % during the forecast period.

Global Bronchodilators Market Overview:

Bronchodilators are the medications prescribed to the individuals having difficulty in breathing. Bronchodilators help to open the airways or bronchial tubes of the lungs by relaxing the bronchial muscles & allow people to breathe well. Bronchodilators are used to treat various respiratory conditions such as Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Allergic Reactions. Asthma affects 5-10% of the population or an estimated 23.4 million people, including 7 million children. There are two forms of Bronchodilators:  Short-acting beta-adrenergic bronchodilators which provide quick relief from asthma.  Long-acting beta-adrenergic bronchodilators are used for preventing asthma attacks or reducing the frequency of symptoms. An increase in the prevalence of asthma and COPD and advancement in technologies drive the global bronchodilators market. Also, the increase in the number of government initiatives and rising healthcare expenditure is expected to fuel the market over the forecast period. Other factors such as the rise in the incidence of chronic respiratory disease due to cigarette smoking also boost the market growth. On the other hand, several side effects associated with bronchodilators such as migraine headaches, nausea, bronchitis, etc. may hinder the growth of the market. Cost of treatment and lack of patient awareness may hamper the growth of the market to some extent. Nevertheless, development in emerging economies is expected to create an array of opportunities in the near future.

Global Bronchodilators Market Regional Insights:

Global Bronchodilators Market To know about the Research Methodology :- Request Free Sample Report According to the regional analysis, North America is expected to dominate the global bronchodilators market due to a rise in the incidence of chronic respiratory diseases, increase in awareness, rising adoption of nasal therapeutics, and presence of leading players of bronchodilators market such AstraZeneca, Teva Pharmaceuticals, etc. Followed by North America, Europe is also expected to dominate the global market. Rising cases of COPD and Asthma are driving the market growth. An estimated 1.2 million people are living with diagnosed COPD, according to the British Lung Foundation. Moreover, around 2% of the whole population and 4.5% of all people aged over 40 live with diagnosed COPD in the UK. APAC region is anticipated to be the fastest-growing region during the forecast period owing to the surge in increasing asthma patients.

Global Bronchodilators Market Segmentation:

The global Bronchodilators market is segmented based on Drug Class and Route of Administration:

Global Bronchodilators Market, By Drug-Class:

• Adrenergic Bronchodilators • Anticholinergic Bronchodilators • Bronchodilator Combinations • Methylxanthines

Global Bronchodilators Market, By Application:

• Asthma • COPD • Others

Global Bronchodilators Market, By Route of Administration:

• Oral • Injectable • Nasal

Scope of Global Bronchodilators Market :Inquire before buying

Drug-Class Segment Analysis:

The Adrenergic Bronchodilators drug class is expected to hold the largest share during the forecast period due to their potency to treat asthma and obstructive lung disease. Adrenergic drugs dilate the bronchial airways by relaxing the surrounding muscles. Global Bronchodilators Market1

Key players operating in Global Bronchodilators Market:

• F. Hoffmann-La Roche • Vectura group • Abbott Laboratories • Gilead Sciences • Novartis AG • Boehringer Ingelheim • GlaxoSmithKline • Merck & Co. • Astrazeneca • Pfizer • Teva Pharmaceuticals • Varenyam Healthcare Pvt. Ltd. • Xencor • Pieris pharmaceuticals • Century pharmaceuticals Limited • Pharmaxis • Adamis Pharmaceuticals • NeoPharm Inc • Paradigm Biopharmaceuticals • Prolexys Pharmaceuticals • Pulmatrix Inc. The objective of the report is to present a comprehensive analysis of the Global Bronchodilators Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Bronchodilators Market dynamics, structure by analyzing the market segments and project the Global Bronchodilators Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Bronchodilators Market make the report investor’s guide.
Global Bronchodilators Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: BRONCHODILATORS Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global BRONCHODILATORS Market Analysis and Forecast 6.1. BRONCHODILATORS Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global BRONCHODILATORS Market Analysis and Forecast, By Drug-Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. BRONCHODILATORS Market Value Share Analysis, By Drug-Class 7.4. BRONCHODILATORS Market Size (US$ Mn) Forecast, By Drug-Class 7.5. BRONCHODILATORS Market Analysis, By Drug-Class 7.6. BRONCHODILATORS Market Attractiveness Analysis, By Drug-Class 8. Global BRONCHODILATORS Market Analysis and Forecast, By Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. BRONCHODILATORS Market Value Share Analysis, By Application 8.4. BRONCHODILATORS Market Size (US$ Mn) Forecast, By Application 8.5. BRONCHODILATORS Market Analysis, By Application 8.6. BRONCHODILATORS Market Attractiveness Analysis, By Application 9. Global BRONCHODILATORS Market Analysis and Forecast By Route of Administration 9.1. Introduction and Definition 9.2. Key Findings 9.3. BRONCHODILATORS Market Value Share Analysis, By Route of Administration 9.4. BRONCHODILATORS Market Size (US$ Mn) Forecast, By Route of Administration 9.5. BRONCHODILATORS Market Analysis, By Route of Administration 9.6. BRONCHODILATORS Market Attractiveness Analysis, By Route of Administration 10. Global BRONCHODILATORS Market Analysis, By Region 10.1. BRONCHODILATORS Market Value Share Analysis, By Region 10.2. BRONCHODILATORS Market Size (US$ Mn) Forecast, By Region 10.3. BRONCHODILATORS Market Attractiveness Analysis, By Region 11. North America BRONCHODILATORS Market Analysis 11.1. Key Findings 11.2. North America BRONCHODILATORS Market Overview 11.3. North America BRONCHODILATORS Market Value Share Analysis, By Drug-Class 11.4. North America BRONCHODILATORS Market Forecast, By Drug-Class 11.4.1. Adrenergic Bronchodilators 11.4.2. Anticholinergic Bronchodilators 11.4.3. Bronchodilator Combinations 11.4.4. Methylxanthines 11.5. North America BRONCHODILATORS Market Value Share Analysis, By Application 11.6. North America BRONCHODILATORS Market Forecast, By Application 11.6.1. Asthma 11.6.2. COPD 11.6.3. Others 11.7. North America BRONCHODILATORS Market Value Share Analysis, By Route of Administration 11.8. North America BRONCHODILATORS Market Forecast, By Route of Administration 11.8.1. Oral 11.8.2. Injectable 11.8.3. Nasal 11.9. North America BRONCHODILATORS Market Value Share Analysis, By Country 11.10. North America BRONCHODILATORS Market Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America BRONCHODILATORS Market Analysis, By Country 11.12. U.S. BRONCHODILATORS Market Forecast, By Drug-Class 11.12.1. Adrenergic Bronchodilators 11.12.2. Anticholinergic Bronchodilators 11.12.3. Bronchodilator Combinations 11.12.4. Methylxanthines 11.13. U.S. BRONCHODILATORS Market Forecast, By Application 11.13.1. Asthma 11.13.2. COPD 11.13.3. Others 11.14. U.S. BRONCHODILATORS Market Forecast, By Route of Administration 11.14.1. Oral 11.14.2. Injectable 11.14.3. Nasal 11.15. Canada BRONCHODILATORS Market Forecast, By Drug-Class 11.15.1. Adrenergic Bronchodilators 11.15.2. Anticholinergic Bronchodilators 11.15.3. Bronchodilator Combinations 11.15.4. Methylxanthines 11.16. Canada BRONCHODILATORS Market Forecast, By Application 11.16.1. Asthma 11.16.2. COPD 11.16.3. Others 11.17. Canada BRONCHODILATORS Market Forecast, By Route of Administration 11.17.1. Oral 11.17.2. Injectable 11.17.3. Nasal 11.18. Mexico BRONCHODILATORS Market Forecast, By Drug-Class 11.18.1. Adrenergic Bronchodilators 11.18.2. Anticholinergic Bronchodilators 11.18.3. Bronchodilator Combinations 11.18.4. Methylxanthines 11.19. Mexico BRONCHODILATORS Market Forecast, By Application 11.19.1. Asthma 11.19.2. COPD 11.19.3. Others 11.20. Mexico BRONCHODILATORS Market Forecast, By Route of Administration 11.20.1. Oral 11.20.2. Injectable 11.20.3. Nasal 11.21. North America BRONCHODILATORS Market Attractiveness Analysis 11.21.1. By Drug-Class 11.21.2. By Application 11.21.3. By Route of Administration 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe BRONCHODILATORS Market Analysis 12.1. Key Findings 12.2. Europe BRONCHODILATORS Market Overview 12.3. Europe BRONCHODILATORS Market Value Share Analysis, By Drug-Class 12.4. Europe BRONCHODILATORS Market Forecast, By Drug-Class 12.4.1. Adrenergic Bronchodilators 12.4.2. Anticholinergic Bronchodilators 12.4.3. Bronchodilator Combinations 12.4.4. Methylxanthines 12.5. Europe BRONCHODILATORS Market Value Share Analysis, By Application 12.6. Europe BRONCHODILATORS Market Forecast, By Application 12.6.1. Asthma 12.6.2. COPD 12.6.3. Others 12.7. Europe BRONCHODILATORS Market Value Share Analysis, By Route of Administration 12.8. Europe BRONCHODILATORS Market Forecast, By Route of Administration 12.8.1. Oral 12.8.2. Injectable 12.8.3. Nasal 12.9. Europe BRONCHODILATORS Market Value Share Analysis, By Country 12.10. Europe BRONCHODILATORS Market Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany BRONCHODILATORS Market Forecast, By Drug-Class 12.11.1. Adrenergic Bronchodilators 12.11.2. Anticholinergic Bronchodilators 12.11.3. Bronchodilator Combinations 12.11.4. Methylxanthines 12.12. Germany BRONCHODILATORS Market Forecast, By Application 12.12.1. Asthma 12.12.2. COPD 12.12.3. Others 12.13. Germany BRONCHODILATORS Market Forecast, By Route of Administration 12.13.1. Oral 12.13.2. Injectable 12.13.3. Nasal 12.14. U.K. BRONCHODILATORS Market Forecast, By Drug-Class 12.14.1. Adrenergic Bronchodilators 12.14.2. Anticholinergic Bronchodilators 12.14.3. Bronchodilator Combinations 12.14.4. Methylxanthines 12.15. U.K. BRONCHODILATORS Market Forecast, By Application 12.15.1. Asthma 12.15.2. COPD 12.15.3. Others 12.16. U.K. BRONCHODILATORS Market Forecast, By Route of Administration 12.16.1. Oral 12.16.2. Injectable 12.16.3. Nasal 12.17. France BRONCHODILATORS Market Forecast, By Drug-Class 12.17.1. Adrenergic Bronchodilators 12.17.2. Anticholinergic Bronchodilators 12.17.3. Bronchodilator Combinations 12.17.4. Methylxanthines 12.18. France BRONCHODILATORS Market Forecast, By Application 12.18.1. Asthma 12.18.2. COPD 12.18.3. Others 12.19. France BRONCHODILATORS Market Forecast, By Route of Administration 12.19.1. Oral 12.19.2. Injectable 12.19.3. Nasal 12.20. Italy BRONCHODILATORS Market Forecast, By Drug-Class 12.20.1. Adrenergic Bronchodilators 12.20.2. Anticholinergic Bronchodilators 12.20.3. Bronchodilator Combinations 12.20.4. Methylxanthines 12.21. Italy BRONCHODILATORS Market Forecast, By Application 12.21.1. Asthma 12.21.2. COPD 12.21.3. Others 12.22. Italy BRONCHODILATORS Market Forecast, By Route of Administration 12.22.1. Oral 12.22.2. Injectable 12.22.3. Nasal 12.23. Spain BRONCHODILATORS Market Forecast, By Drug-Class 12.23.1. Adrenergic Bronchodilators 12.23.2. Anticholinergic Bronchodilators 12.23.3. Bronchodilator Combinations 12.23.4. Methylxanthines 12.24. Spain BRONCHODILATORS Market Forecast, By Application 12.24.1. Asthma 12.24.2. COPD 12.24.3. Others 12.25. Spain BRONCHODILATORS Market Forecast, By Route of Administration 12.25.1. Oral 12.25.2. Injectable 12.25.3. Nasal 12.26. Sweden BRONCHODILATORS Market Forecast, By Drug-Class 12.26.1. Adrenergic Bronchodilators 12.26.2. Anticholinergic Bronchodilators 12.26.3. Bronchodilator Combinations 12.26.4. Methylxanthines 12.27. Sweden BRONCHODILATORS Market Forecast, By Application 12.27.1. Asthma 12.27.2. COPD 12.27.3. Others 12.28. Sweden BRONCHODILATORS Market Forecast, By Route of Administration 12.28.1. Oral 12.28.2. Injectable 12.28.3. Nasal 12.29. CIS countries BRONCHODILATORS Market Forecast, By Drug-Class 12.29.1. Adrenergic Bronchodilators 12.29.2. Anticholinergic Bronchodilators 12.29.3. Bronchodilator Combinations 12.29.4. Methylxanthines 12.30. CIS countries BRONCHODILATORS Market Forecast, By Application 12.30.1. Asthma 12.30.2. COPD 12.30.3. Others 12.31. CIS countries BRONCHODILATORS Market Forecast, By Route of Administration 12.31.1. Oral 12.31.2. Injectable 12.31.3. Nasal 12.32. Rest of Europe BRONCHODILATORS Market Forecast, By Drug-Class 12.32.1. Adrenergic Bronchodilators 12.32.2. Anticholinergic Bronchodilators 12.32.3. Bronchodilator Combinations 12.32.4. Methylxanthines 12.33. Rest of Europe BRONCHODILATORS Market Forecast, By Application 12.33.1. Asthma 12.33.2. COPD 12.33.3. Others 12.34. Rest of Europe BRONCHODILATORS Market Forecast, By Route of Administration 12.34.1. Oral 12.34.2. Injectable 12.34.3. Nasal 12.35. Europe BRONCHODILATORS Market Attractiveness Analysis 12.35.1. By Application 12.35.2. By Drug-Class 12.35.3. By Route of Administration 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific BRONCHODILATORS Market Analysis 13.1. Key Findings 13.2. Asia Pacific BRONCHODILATORS Market Overview 13.3. Asia Pacific BRONCHODILATORS Market Value Share Analysis, By Drug-Class 13.4. Asia Pacific BRONCHODILATORS Market Forecast, By Drug-Class 13.4.1. Adrenergic Bronchodilators 13.4.2. Anticholinergic Bronchodilators 13.4.3. Bronchodilator Combinations 13.4.4. Methylxanthines 13.5. Asia Pacific BRONCHODILATORS Market Value Share Analysis, By Application 13.6. Asia Pacific BRONCHODILATORS Market Forecast, By Application 13.6.1. Asthma 13.6.2. COPD 13.6.3. Others 13.7. Asia Pacific BRONCHODILATORS Market Value Share Analysis, By Route of Administration 13.8. Asia Pacific BRONCHODILATORS Market Forecast, By Route of Administration 13.8.1. Oral 13.8.2. Injectable 13.8.3. Nasal 13.9. Asia Pacific BRONCHODILATORS Market Value Share Analysis, By Country 13.10. Asia Pacific BRONCHODILATORS Market Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific BRONCHODILATORS Market Analysis, By Country 13.12. China BRONCHODILATORS Market Forecast, By Drug-Class 13.12.1. Adrenergic Bronchodilators 13.12.2. Anticholinergic Bronchodilators 13.12.3. Bronchodilator Combinations 13.12.4. Methylxanthines 13.13. China BRONCHODILATORS Market Forecast, By Application 13.13.1. Asthma 13.13.2. COPD 13.13.3. Others 13.14. China BRONCHODILATORS Market Forecast, By Route of Administration 13.14.1. Oral 13.14.2. Injectable 13.14.3. Nasal 13.15. India BRONCHODILATORS Market Forecast, By Drug-Class 13.15.1. Adrenergic Bronchodilators 13.15.2. Anticholinergic Bronchodilators 13.15.3. Bronchodilator Combinations 13.15.4. Methylxanthines 13.16. India BRONCHODILATORS Market Forecast, By Application 13.16.1. Asthma 13.16.2. COPD 13.16.3. Others 13.17. India BRONCHODILATORS Market Forecast, By Route of Administration 13.17.1. Oral 13.17.2. Injectable 13.17.3. Nasal 13.18. Japan BRONCHODILATORS Market Forecast, By Drug-Class 13.18.1. Adrenergic Bronchodilators 13.18.2. Anticholinergic Bronchodilators 13.18.3. Bronchodilator Combinations 13.18.4. Methylxanthines 13.19. Japan BRONCHODILATORS Market Forecast, By Application 13.19.1. Asthma 13.19.2. COPD 13.19.3. Others 13.20. Japan BRONCHODILATORS Market Forecast, By Route of Administration 13.20.1. Oral 13.20.2. Injectable 13.20.3. Nasal 13.21. South Korea BRONCHODILATORS Market Forecast, By Drug-Class 13.21.1. Adrenergic Bronchodilators 13.21.2. Anticholinergic Bronchodilators 13.21.3. Bronchodilator Combinations 13.21.4. Methylxanthines 13.22. South Korea BRONCHODILATORS Market Forecast, By Application 13.22.1. Asthma 13.22.2. COPD 13.22.3. Others 13.23. South Korea BRONCHODILATORS Market Forecast, By Route of Administration 13.23.1. Oral 13.23.2. Injectable 13.23.3. Nasal 13.24. Australia BRONCHODILATORS Market Forecast, By Drug-Class 13.24.1. Adrenergic Bronchodilators 13.24.2. Anticholinergic Bronchodilators 13.24.3. Bronchodilator Combinations 13.24.4. Methylxanthines 13.25. Australia BRONCHODILATORS Market Forecast, By Application 13.25.1. Asthma 13.25.2. COPD 13.25.3. Others 13.26. Australia BRONCHODILATORS Market Forecast, By Route of Administration 13.26.1. Oral 13.26.2. Injectable 13.26.3. Nasal 13.27. ASEAN BRONCHODILATORS Market Forecast, By Drug-Class 13.27.1. Adrenergic Bronchodilators 13.27.2. Anticholinergic Bronchodilators 13.27.3. Bronchodilator Combinations 13.27.4. Methylxanthines 13.28. ASEAN BRONCHODILATORS Market Forecast, By Application 13.28.1. Asthma 13.28.2. COPD 13.28.3. Others 13.29. ASEAN BRONCHODILATORS Market Forecast, By Route of Administration 13.29.1. Oral 13.29.2. Injectable 13.29.3. Nasal 13.30. Rest of Asia Pacific BRONCHODILATORS Market Forecast, By Drug-Class 13.30.1. Adrenergic Bronchodilators 13.30.2. Anticholinergic Bronchodilators 13.30.3. Bronchodilator Combinations 13.30.4. Methylxanthines 13.31. Rest of Asia Pacific BRONCHODILATORS Market Forecast, By Application 13.31.1. Asthma 13.31.2. COPD 13.31.3. Others 13.32. Rest of Asia Pacific BRONCHODILATORS Market Forecast, By Route of Administration 13.32.1. Oral 13.32.2. Injectable 13.32.3. Nasal 13.33. Asia Pacific BRONCHODILATORS Market Attractiveness Analysis 13.33.1. By Drug-Class 13.33.2. By Application 13.33.3. By Route of Administration 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa BRONCHODILATORS Market Analysis 14.1. Key Findings 14.2. Middle East & Africa BRONCHODILATORS Market Overview 14.3. Middle East & Africa BRONCHODILATORS Market Value Share Analysis, By Drug-Class 14.4. Middle East & Africa BRONCHODILATORS Market Forecast, By Drug-Class 14.4.1. Adrenergic Bronchodilators 14.4.2. Anticholinergic Bronchodilators 14.4.3. Bronchodilator Combinations 14.4.4. Methylxanthines 14.5. Middle East & Africa BRONCHODILATORS Market Value Share Analysis, By Application 14.6. Middle East & Africa BRONCHODILATORS Market Forecast, By Application 14.6.1. Asthma 14.6.2. COPD 14.6.3. Others 14.7. Middle East & Africa BRONCHODILATORS Market Value Share Analysis, By Route of Administration 14.8. Middle East & Africa BRONCHODILATORS Market Forecast, By Route of Administration 14.8.1. Oral 14.8.2. Injectable 14.8.3. Nasal 14.9. Middle East & Africa BRONCHODILATORS Market Value Share Analysis, By Country 14.10. Middle East & Africa BRONCHODILATORS Market Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa BRONCHODILATORS Market Analysis, By Country 14.12. GCC Countries BRONCHODILATORS Market Forecast, By Drug-Class 14.12.1. Adrenergic Bronchodilators 14.12.2. Anticholinergic Bronchodilators 14.12.3. Bronchodilator Combinations 14.12.4. Methylxanthines 14.13. GCC Countries BRONCHODILATORS Market Forecast, By Application 14.13.1. Asthma 14.13.2. COPD 14.13.3. Others 14.14. GCC Countries BRONCHODILATORS Market Forecast, By Route of Administration 14.14.1. Oral 14.14.2. Injectable 14.14.3. Nasal 14.15. South Africa BRONCHODILATORS Market Forecast, By Drug-Class 14.15.1. Adrenergic Bronchodilators 14.15.2. Anticholinergic Bronchodilators 14.15.3. Bronchodilator Combinations 14.15.4. Methylxanthines 14.16. South Africa BRONCHODILATORS Market Forecast, By Application 14.16.1. Asthma 14.16.2. COPD 14.16.3. Others 14.17. South Africa BRONCHODILATORS Market Forecast, By Route of Administration 14.17.1. Oral 14.17.2. Injectable 14.17.3. Nasal 14.18. Nigeria BRONCHODILATORS Market Forecast, By Drug-Class 14.18.1. Adrenergic Bronchodilators 14.18.2. Anticholinergic Bronchodilators 14.18.3. Bronchodilator Combinations 14.18.4. Methylxanthines 14.19. Nigeria BRONCHODILATORS Market Forecast, By Application 14.19.1. Asthma 14.19.2. COPD 14.19.3. Others 14.20. Nigeria BRONCHODILATORS Market Forecast, By Route of Administration 14.20.1. Oral 14.20.2. Injectable 14.20.3. Nasal 14.21. Egypt BRONCHODILATORS Market Forecast, By Drug-Class 14.21.1. Adrenergic Bronchodilators 14.21.2. Anticholinergic Bronchodilators 14.21.3. Bronchodilator Combinations 14.21.4. Methylxanthines 14.22. Egypt BRONCHODILATORS Market Forecast, By Application 14.22.1. Asthma 14.22.2. COPD 14.22.3. Others 14.23. Egypt BRONCHODILATORS Market Forecast, By Route of Administration 14.23.1. Oral 14.23.2. Injectable 14.23.3. Nasal 14.24. Rest of Middle East & Africa BRONCHODILATORS Market Forecast, By Drug-Class 14.24.1. Adrenergic Bronchodilators 14.24.2. Anticholinergic Bronchodilators 14.24.3. Bronchodilator Combinations 14.24.4. Methylxanthines 14.25. Rest of Middle East & Africa BRONCHODILATORS Market Forecast, By Application 14.25.1. Asthma 14.25.2. COPD 14.25.3. Others 14.26. Rest of Middle East & Africa BRONCHODILATORS Market Forecast, By Route of Administration 14.26.1. Oral 14.26.2. Injectable 14.26.3. Nasal 14.27. Middle East & Africa BRONCHODILATORS Market Attractiveness Analysis 14.27.1. By Drug-Class 14.27.2. By Application 14.27.3. By Route of Administration 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America BRONCHODILATORS Market Analysis 15.1. Key Findings 15.2. South America BRONCHODILATORS Market Overview 15.3. South America BRONCHODILATORS Market Value Share Analysis, By Drug-Class 15.4. South America BRONCHODILATORS Market Forecast, By Drug-Class 15.4.1. Adrenergic Bronchodilators 15.4.2. Anticholinergic Bronchodilators 15.4.3. Bronchodilator Combinations 15.4.4. Methylxanthines 15.5. South America BRONCHODILATORS Market Value Share Analysis, By Application 15.6. South America BRONCHODILATORS Market Forecast, By Application 15.6.1. Asthma 15.6.2. COPD 15.6.3. Others 15.7. South America BRONCHODILATORS Market Value Share Analysis, By Route of Administration 15.8. South America BRONCHODILATORS Market Forecast, By Route of Administration 15.8.1. Oral 15.8.2. Injectable 15.8.3. Nasal 15.9. South America BRONCHODILATORS Market Value Share Analysis, By Country 15.10. South America BRONCHODILATORS Market Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America BRONCHODILATORS Market Analysis, By Country 15.12. Brazil BRONCHODILATORS Market Forecast, By Drug-Class 15.12.1. Adrenergic Bronchodilators 15.12.2. Anticholinergic Bronchodilators 15.12.3. Bronchodilator Combinations 15.12.4. Methylxanthines 15.13. Brazil BRONCHODILATORS Market Forecast, By Application 15.13.1. Asthma 15.13.2. COPD 15.13.3. Others 15.14. Brazil BRONCHODILATORS Market Forecast, By Route of Administration 15.14.1. Oral 15.14.2. Injectable 15.14.3. Nasal 15.15. Colombia BRONCHODILATORS Market Forecast, By Drug-Class 15.15.1. Adrenergic Bronchodilators 15.15.2. Anticholinergic Bronchodilators 15.15.3. Bronchodilator Combinations 15.15.4. Methylxanthines 15.16. Colombia BRONCHODILATORS Market Forecast, By Application 15.16.1. Asthma 15.16.2. COPD 15.16.3. Others 15.17. Colombia BRONCHODILATORS Market Forecast, By Route of Administration 15.17.1. Oral 15.17.2. Injectable 15.17.3. Nasal 15.18. Argentina BRONCHODILATORS Market Forecast, By Drug-Class 15.18.1. Adrenergic Bronchodilators 15.18.2. Anticholinergic Bronchodilators 15.18.3. Bronchodilator Combinations 15.18.4. Methylxanthines 15.19. Argentina BRONCHODILATORS Market Forecast, By Application 15.19.1. Asthma 15.19.2. COPD 15.19.3. Others 15.20. Argentina BRONCHODILATORS Market Forecast, By Route of Administration 15.20.1. Oral 15.20.2. Injectable 15.20.3. Nasal 15.21. Rest of South America BRONCHODILATORS Market Forecast, By Drug-Class 15.21.1. Adrenergic Bronchodilators 15.21.2. Anticholinergic Bronchodilators 15.21.3. Bronchodilator Combinations 15.21.4. Methylxanthines 15.22. Rest of South America BRONCHODILATORS Market Forecast, By Application 15.22.1. Asthma 15.22.2. COPD 15.22.3. Others 15.23. Rest of South America BRONCHODILATORS Market Forecast, By Route of Administration 15.23.1. Oral 15.23.2. Injectable 15.23.3. Nasal 15.24. South America BRONCHODILATORS Market Attractiveness Analysis 15.24.1. By Drug-Class 15.24.2. By Application 15.24.3. By Route of Administration 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Component 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. F. Hoffmann-La Roche 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Vectura group 16.3.3. Abbott Laboratories 16.3.4. Gilead Sciences 16.3.5. Novartis AG 16.3.6. Boehringer Ingelheim 16.3.7. GlaxoSmithKline 16.3.8. Merck & Co. 16.3.9. Astrazeneca 16.3.10. Pfizer 16.3.11. Teva Pharmaceuticals 16.3.12. Varenyam Healthcare Pvt. Ltd. 16.3.13. Xencor 16.3.14. Pieris pharmaceuticals 16.3.15. Century pharmaceuticals Limited 16.3.16. Pharmaxis 16.3.17. Adamis Pharmaceuticals 16.3.18. NeoPharm Inc 16.3.19. Paradigm Biopharmaceuticals 16.3.20. Prolexys Pharmaceuticals 16.3.21. Pulmatrix Inc. 17. Primary key Insights

About This Report

Report ID 81931
Category Healthcare
Published Date February 2021
Updated Date
Contact Us